Table III.
Pathological tumor response and clinicopathological factors.
| Pathological tumor response (%)
|
||||||
|---|---|---|---|---|---|---|
| Clinicopathological factors | 0 | 1 | 2 | 3 | Total | P-value |
| Age (years) | ||||||
| ≤50 | 3 (2.2) | 43 (32.1) | 44 (32.8) | 44 (32.8) | 134 | 0.41 |
| ≥51 | 1 (0.8) | 38 (29.2) | 37 (28.5) | 54 (41.5) | 130 | |
| Body mass index | ||||||
| ≤23 | 1 (0.7) | 43 (30.7) | 39 (27.9) | 57 (40.7) | 140 | 0.37 |
| >23 | 3 (2.5) | 36 (29.5) | 42 (34.4) | 41 (33.6) | 122 | |
| Clinical tumor size | ||||||
| T1 | 1 (8.3) | 2 (16.7) | 0 (0.0) | 1 (8.3) | 12 | 0.046 |
| T2 | 2 (1.3) | 39 (25.5) | 44 (28.8) | 68 (44.4) | 153 | |
| T3 | 0 (0.0) | 27 (42.9) | 20 (31.7) | 16 (25.4) | 63 | |
| T4 | 1 (2.8) | 13 (36.1) | 13 (36.1) | 9 (25.0) | 36 | |
| Clinical nodal status | ||||||
| N0 | 3 (4.8) | 16 (25.4) | 15 (23.8) | 29 (46.0) | 63 | 0.11 |
| N1 | 1 (0.7) | 46 (32.2) | 44 (30.8) | 52 (36.4) | 143 | |
| N2 | 0 (0.0) | 10 (32.3) | 9 (29.0) | 12 (38.7) | 31 | |
| N3 | 0 (0.0) | 9 (33.3) | 13 (48.1) | 5 (18.5) | 27 | |
| Estrogen receptor | ||||||
| Negative | 2 (1.7) | 26 (22.6) | 18 (15.7) | 69 (60.0) | 115 | <0.0001 |
| Positive | 2 (1.3) | 55 (36.9) | 63 (42.3) | 29 (19.5) | 149 | |
| Progesterone receptor | ||||||
| Negative | 3 (2.1) | 35 (24.6) | 26 (18.3) | 78 (54.9) | 142 | <0.0001 |
| Positive | 1 (0.8) | 46 (37.8) | 55 (45.1) | 20 (16.4) | 122 | |
| HER2 | ||||||
| 0 | 2 (5.3) | 15 (39.5) | 16 (42.1) | 5 (13.2) | 38 | <0.0001 |
| 1+ | 2 (2.6) | 29 (38.2) | 24 (31.6) | 21 (27.6) | 76 | |
| 2+ | 0 (0.0) | 25 (39.7) | 17 (27.0) | 21 (33.3) | 63 | |
| 3+ | 0 (0.0) | 12 (13.8) | 24 (27.6) | 51 (58.6) | 87 | |
| Molecular subtype | ||||||
| Luminal/HER2-negative | 2 (2.2) | 37 (39.8) | 41 (44.1) | 13 (14.0) | 93 | <0.0001 |
| Luminal/HER2-positive | 0 (0.0) | 15 (27.8) | 22 (40.7) | 17 (31.5) | 54 | |
| Non-luminal/ HER2-positive | 0 (0.0) | 7 (10.6) | 11 (16.7) | 48 (72.7) | 66 | |
| Triple-negative | 2 (4.5) | 17 (38.6) | 5 (11.4) | 20 (45.5) | 44 | |
| Histological type | ||||||
| IDC NOS | 3 (1.2) | 73 (29.6) | 74 (30.0) | 97 (39.3) | 247 | 0.026 |
| Others | 1 (5.9) | 8 (82.4) | 7 (47.1) | 1 (5.9) | 17 | |
| Total | 4 (1.5) | 81 (30.7) | 81 (30.7) | 98 (37.1) | 264 | |
HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; NOS, not otherwise specified. A total of two and seven cases were missing data on body mass index and molecular subtype, respectively.